Webinar

Parallel screening technologies to fix bioavailability challenges: A case study by Trio and Catalent

Published

Format: External webinar | Document type: Webinar

Parallel screening technologies to fix bioavailability challenges: A case study by Trio and Catalent
Early in a molecule’s development, how do scientists decide which formulation strategy to take and whether to spend time developing a dosage form or just hurry into phase I with a sub-optimal drug delivery system? Making a poor choice could increase the risk of failure and/or open the door to wasted time and money later on. This webinar shows how Trio Medicines and Catalent overcame bioavailability challenge for a poorly soluble molecule that treats reflux disease and gastric neuroendocrine tumor, and advanced it to animal PK study rapidly with the optimal formulation. We will discuss how to characterize a molecule, apply the right prediction model, and select the most suitable delivery technology for a poorly soluble small molecule using an API sparing parallel screening protocol under the guidance of a technical expert. Candidate formulations with 2 weeks’ stability were ready in 12 weeks.

Speakers

Malcolm Boyce Malcolm Boyce Chief Executive
TRIO Medicines Limited

Stephen Tindal Stephen Tindal Director of Scientific Affairs
Catalent Pharma Solutions

Related resources from Catalent Pharma Solutions

Show more

Supplier info centre